Insulin resistance in chronic hepatitits C;Importância da resistência insulínica na hepatite C crônica

Arquivos de Gastroenterologia

Volumn 44, Issue 2, 2007, Pages 178-184

  Parise, Edison Roberto ^a,b   De Oliveira, Ana Cláudia ^a  

^a FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^b NONE   (Brazil)

Author keywords

Chronic; Diabetes mellitus, type 2; Fatty liver; Hepatitis C; Insulin resistance; Interferons; Liver cirrhosis

Indexed keywords

INSULIN RECEPTOR; IRON; PEGINTERFERON; RIBAVIRIN; TUMOR NECROSIS FACTOR; ALPHA2A INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; PEGINTERFERON ALFA-2A; PEGINTERFERON ALPHA2A; UNCLASSIFIED DRUG;

DISEASE ASSOCIATION; FATTY LIVER; GENOTYPE; GLUCOSE TRANSPORT; HEPATITIS C; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PROTEIN PHOSPHORYLATION; REVIEW; VIROLOGY; LIVER CIRRHOSIS; PATHOPHYSIOLOGY;

ANTIVIRAL AGENTS; DIABETES MELLITUS, TYPE 2; FATTY LIVER; HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE; INTERFERON ALFA-2A; LIVER CIRRHOSIS; POLYETHYLENE GLYCOLS; RIBAVIRIN;

EID: 35649018234     PISSN: 00042803     EISSN: 16784219     Source Type: Journal    
DOI: 10.1590/s0004-28032007000200017     Document Type: Review

References (72)

1. Allison ME, Wreghitt T, Palmer CR, Alexander GJ. Evidence for a link between hepatitis C vírus infection and diabetes mellitus in a cirrhotic population. J Hepatol. 1994;21:1135-9.
2. Aytug S, Reich D, Sapiro LE, Bernstein D, Begum N. Impaired IRS-1/PI3-kinase signaling in patients with HCV: a machanism for increased prevalence of type 2 diabetes. Hepatology. 2003;38:1384-92.
3. Bonkovsky HL, Banner BF, Rothman AL. Iron and chronic viral hepatitis. Hepatology. 1997;25:759-68.
4. Bonnefont-Rousselot D, Ratziu V, Giral P, Charlotte F, Beucler I, Poynard T. Blood oxidative stress markers are unreliable markers of hepatic steatosis. Aliment Pharmacol Ther. 2006;23:91-8.
5. Chitturi S, Farrell GC. Etiopathogenesis of nonalcoholic steatohepatitis. Semin Liver Dis. 2001,21:27-41.
6. D'Souza R, Sabin CA, Foster GR. Insulin resistance plays a significant role in liver fibrosis in chronic hepatitis C and in the response to antiviral therapy. Am J Gastroenterol. 2005;100:1509-15.
7. Day CP, James OF. Steatohepatitis: A tale of two "hits"? Gastroenterology. 1998;114:842-5.
8. De Maria N, Colantoni A, Fagiuoli S, Liu GJ, Rogers BK, Farinati F, Van Thiel DH, Floyd RA. Association between reactive oxygen species and disease activity in chronic hepatitis C. Free Radic Biol Med. 1996;21:291-5.
9. Ding X, Saxena NK, Lin S, Xu A, Srinivasan S, Anania FA. The roles of leptin and adiponectin: a novel paradigm in adipocytokine regulation of liver fibrosis and stellate cell biology. Am J Pathol. 2005;166:1655-69.
10. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease:predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001;121:91-100.
11. Durante-Mangoni E, Zampino R, Marrone A, Tripodi MF, Rinaldi L, Restivo L, Cioffi M, Ruggiero G, Adinolfi LE. Hepatic steatosis and insulin resistance are associated with serum imbalance of adiponectin/tumour necrosis factor-alpha in chronic hepatits C patients. Aliment Pharmacol Ther. 2006;24:1349-57
12. Ellidokuz E, Comlekci A, Ellidokuz H, Akpinar H, Gokce C, Tankurt E, Sagol O, Simsek I, Gonen O. The role of serum leptin levels in chronic hepatitis C with steatosis. Hepatogastroenterology. 2003;50 (suppl 2):cclxix-cclxxii
13. Falck-Ytter Y, Younossi ZM, Marchesini G, McCullough AJ. Clinical features and natural history of nonalcoholic steatosis syndrome. Semin Liver Dis. 2001;21:17-26.
14. Fargion S, Fracanzani AL, Rossini A,Borzio M, Riggio O, Belloni G, Bissoli F, Ceriani R, Ballare M, Massari M, Trischitta C. Fiore P, Orlandi A, Morini L, Mattioli M, Oldani S, Cesana B, Fiorelli G. Iron reduction and sustained response to interferon α therapy in patients with chronic hepatitis C: results of an Italian multicenter randomized study. Am J Gastroenterol. 2002;97:1204-10.
15. Fartoux L, Poujol-Robert A, Guechot J, Wendum D, Poupon R, Serfaty L. Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C. Gut. 2005;54:1003-8.
16. Fong DG, Nehra V, Lindor KD, Buchman AL. Metabolic and nutritional considerations in nonalcoholic fatty liver. Hepatology. 2000;32:3-10.
17. Fontana RJ, Israel J, LeClair P, Banner BF, Tortorelli K, Grace N, Levine RA, Fiarman G, Thiim M, Tavill AS, Bonkovsky HL. Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial. Hepatology. 2000;31:730-6.
18. Furutani M, Nakashima T, Sumida Y, Hirohama A, Yoh T, Kakisak Y, Mitsuyoshi H, Senmaru H, Okanoue T. Insulin resistance beta-cell function and serum ferritin levels in non diabetic patients with hepatitis C vírus infection. Liver Int. 2003;23:294-9.
19. Garrido-Serrano A, Guerrero Igea FJ, Lepe Jimenez JA, Palomo Gil S, Grilo Reina A. Hyperinsulinemia in cirrhotic patients infected with hepatitis C vírus. Gastroenterol Hepatol. 2001;24:127-31.
20. Grimbert S, Valensi P, Levy-Marchal C, Perret G, Richardet JP, Raffloux C, Trinchet JC, Beaugrand M. High prevalence of diabetes mellitus in patients with chronic hepatitis C: a case-control study. Gastroenterol Clin Biol 1996;20:544-8.
21. Guillygomarc'h A, Mendler MH, Moirand R, Lainé F, Quentin V, David V, Brissot P, Deugnier Y. Venesection therapy of insulin resistance-associated hepatic iron overload. J Hepatol. 2001;35:344-9.
22. Hickman IJ, Clouston AD, Macdonald GA, Purdie DM, Prins JB, Ash S, Jonsson JR, Powell EE. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut. 2002;51:89-94.
23. Houglum K, Venkataramani A, Lyche K, Chojkier M. A pilot study of the effects of d-alpha-tocopherol on hepatic stellate cell activation in chronic hepatitis C. Gastroenterology. 1997;113:1069-73.
24. Hourigan LK, Macdonald GA, Purdie D, Whitehall VH, Shorthouse C, Clouston A, Powell EE. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology. 1999;29:1215-19.
25. Hu K-Q, Kyulo NL, Esrailian E, Thompson K, Chase R, Hillebrand DJ, Runyon BA. Overweight and obesity, hepatic steatosis and progression of chronic hepatitis C: a retrospective study on a large cohort of patients in the United States. J Hepatol. 2004;40:147-54.
26. Hui JM, Sud A, Farrel GC, Bandara P, Byth K, Kench JG, McCaughan GW, George J. Insulin resistance is associated with chronic hepatitis C and virus infection fibrosis progression. Gastroenterology. 2003;125:1695-704.
27. Hui JM, Hodge A, Farrell GC, Kench JG, Kriketos A, George J. Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology. 2004:40:46-54.
28. Ishizaka Y, Ishizaka N, Takahashi E, Toda EE, Hashimoto H, Nagai R, Yamakado M. Association between hepatitis C seropositivity, carotid artery plaque and intima-media thickening. Lancet. 2002,359:133-5.
29. Jain SK, Pemberton PW, Smith A, McMahon RF, Burrows PC, Aboutwerat A, Warnes TW. Oxidative stress in chronic hepatitis C: not just a features late stage disease. J Hepatol. 2002;36:805-11.
30. Jehn M, Clark JM and Guallar E. Serum ferritin and risk of the metabolic syndrome in US adults. Diabetes Care. 2004;27:2422-8
31. Jonsson JR, Mosdrn AR, Hickman JJ, Richardson MM, Kaser S, Clouston AD, Powell EE, Tieg H. Adiponectin and its receptors in patients with chronic hepatitis C .J Hepatol. 2005;43:929-36
32. Kamaguchi T, Ide T, Taniguchi E, Hirano E, Itou M, Sumie S, Nagao Y, Yanagimoto C, Hanada S, Koga H, Sata M. Clearance of HCV improves insulin resistance, beta-cell function and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastoenterol. 2007;102:570-6.
33. Kaser S, Moschen AR, Cayon A, Kaser A, Crespo J, Pons Romero F, Ebenbichler CF, Patsch IR, Tilg H. Adiponectin and its receptors in nonalcoholic steatohepatitis. Gut. 2005;54:117-21.
34. Kitase A, Hino K, Furutani T, Okuda M, Gondo T, Hidaka I, Hara Y, Yamaguchi Y, Okita K. In situ detection of oxidized n-3 polyunsaturated fatty acids in chronic hepatitis C: correlation with hepatic steatosis. J Gastroenterol. 2005;40:617-24.
35. Knobler H, Schihmanter R, Zifroni A, Fenakel G, Strathdee AS. A increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. Mayo Clin Proc. 2000,75:355-9.
36. Lecube A, Hernandez C, Genesca J, Esteban JI, Jardi R, Garcia L, Simo R. Diabetes is the main factor accounting for the high ferritin levels detected in chronic hepatitis C virus infection. Diab Care. 2004;27:2669-75.
37. Lecube A, Hérnandez C, Genescà J, Simó R. Proinflammatory cytocines, insulin resistance, and insulin secretion in chronic hepatitis C patients. Diabetes Care. 2006,29:1096-101.
38. Lee KS, Buck M, Houglum K, Chojkier M. Activation of hepatic stellate cells by TGF alpha and collagen type I is mediated by oxidative stress through c-myb expression. J Clin Invest. 1995;96:2461-8.
39. Lonardo A, Adinolfi LE, Loria P, Carulli N, RuggieroG, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extra-hepatic disease. Gastroenterology. 2004;126:586-97
40. Ludwig, J; Viggiano, TR; McGill, DB; Ott, BJ. Nonalcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980;55:434-8.
41. Martin BC, Warram JH, Krolewski AS, Bergman RN, Soeldner JS, Kann CR. Role of glucose and insulin resistance in development of type 2 diabetes mellitus; results of 25-year follow-up study. Lancet. 1992;340:920-9.
42. Martinelli AL, Ramalho LN, Zucoloto S. Hepatic stellate cells in hepatitis C patients: Relationship with liver iron deposits and severity of liver disease. J Gastroenterol Hepatol. 2004,19:91-8.
43. Mehta SH, Brancati FL, Sulkowski MS, Strathdee SA, Szklo M, Thomas DL. Prevalence of type 2 diabetes mellitus among persons with hepatitis C vírus infection in the United States. Ann Intern Med. 2000;133:592-9.
44. Mendler M, Turlin B, Moirand R, Jouanolle A, Sapey T, Guyader D, Le Gall Jy, Brissot P, David V, Daugnier Y. Insulin resistance-associated hepatic iron overload. Gastroenterology. 1999;117:1155-63.
45. Moriya K, Yotsuyanagi H, Shintani Y, Fujie H, Ishibashi K, Matsuura Y, Miyamura T, Koike K. Hepatitis C vírus core protein induces hepatic steatosis in transgenic mice. J Gen Virol. 1997;78:1527-31.
46. Muzzi A, Leandro G, Rubbia-Brandt L, James R, Keiser O, Mallinverni R, Dufour J-F, Helbling B, Hadengue A, Gonvers J-J, Müllhaupt B, Cerny A, Mondelli MU, Negro F. Insulin resistance is associated with liver fibrosis in non-diabetic chronic hepatitis C. J Hepatol. 2005;42:41-6.
47. Oliveira AC, Catarino RM, Nogueira MD, Leite-Mor MM, Giovarotti K, Junqueira VB, Lanzoni V, Parise ER. Resistência insulínica na hepatite crônica pelo vírus C, genótipo não-3, esta associada a marcadores de estresse oxidativo independente da presença de esteatose. GED. 2005;24 (supl 2):93.
48. Oliveira AC, Salgado AL, Junqueira V, Catarino R, Parise ER. Resistência à insulina e estresse oxidativo na hepatite C e na doença hepática gordurosa não alcoólica. GED. 2005;24 (supl. 2):83s.
49. Parise ER, Oliveira AC, Conceição RDO, Amaral AC, Leite K. Response to treatment with interferon alpha and ribavirin in patients with chronic hepatitis C vírus genotypes 2 and 3 depends on the degree of hepatic fibrosis. Braz J Infect Disease. 2006;10:78-81.
50. Powell E, Cooksley WG, Hanson R, Searle J, Halliday JW, Powell LW. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology. 1990;11:74-80.
51. Poynard T, Ratziu V, Charlotte F, Goodman Z, Mchutchison J, Albrecht J. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol. 2001;34:730-9.
52. Poynard T, Ratziu V, McHutchison J, Manns M, Goodman Z, Zeuzem S, Younossi Z, Albrecht J. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology. 2003;38:75-85.
53. Ramm GA, Ruddell RG. Hepatotoxicity of iron overload: mechanisms of iron-induced hepatic fibrogenesis. Sem Liver Dis. 2005;25:433-49.
54. Reid, A. Nonalcoholic steatohepatitis. Gastroenterology. 2001;121:710-23.
55. Romero-Gomez M, Villoria MD, Andrade RJ, Salmeron J, Diago M, Fernandez-Rodriguez CM, Corpas R, Cruz M, Grande L, Vasquez L, Munoz-De-Rueda P, Lopez-Serrano P, Gilá A, Gutierrez ML, Perez C, Ruiz-Extremera A, Suarez E, Castillo J. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology. 2005;128:636-41.
56. Romero-Gómez M. The role of insulin resistance in chronic hepatitis C. Hepatology Rev. 2006;3:32-9.
57. Rubbia-Brandt L, Fabris P, Paganin S, Leandro G, Male PJ, Giostra E, Carlotto A, Bozzola L, Smedile A, Negro F. Steatosis affects chronic hepatitis C progression in a genotype specific way. Gut. 2004;53:406-12.
58. Sanyal AJ, Contos MJ, Sterling RK Luketic VA, Shiffman ML, Stravitz RT, Miles AS. Nonalcoholic fatty liver disease in patients with hepatitis C is associated with features of the metabolic syndrome. Am J Gastroenterol. 2003;98:2064-71.
59. Sanyal, AJ, Chand N, Comar K, Mirshahi F. Hyperinsulinemia blocks the inhibition of hepatitis C vírus replication by interferon: mechanism for failure of interferon therapy in subjects with HCV and nonalcoholic fatty liver disease. Hepatology. 2004;40:179a.
60. Sebastiani G, Vario A, Alberti A. Diabetes is the main factor accounting for the high ferritin levels detected in chronic hepatitis C virus infection. Response to Lecube et al. Diabetes Care. 2005;28:1838-9.
61. Serfaty L, Andreani T, Giral P, Carbonell N, Chazouilleres O, Poupon R. Hepatitis C virus induced hypobetalipoproteinemia: a possible mechanism for steatosis in chronic hepatitis C. J Hepatol. 2001;34:428-34.
62. Sumida Y, Kanemasa K, Fukumoto K, Yoshida N, Sakai K. Effects of dietary iron reduction versus phlebotomy in patients with chronic hepatitis C: results from a randomized controlled trial on 40 japanese patients. Int Med. 2007;46:637-42.
63. Svegliati Baroni G, D'Ambrosio L, Ferretti G, Casini A, DiSario A, Salzano R, Ridolfi F, Saccomanno S, Jezequiel AM, Benedetti A. Fibrogenic effect of oxidative stress on rat hepatic stellate cells. Hepatology. 1998;27:720-6.
64. Tambascia MA, Geloneze Neto B. Resistência à insulina. In Godoy-Matos AF, editor. Síndrome Metabólica. São Paulo: Atheneu; 2005.p.47-53.
65. Valenti L, Francanzani AL, Dongiovanni P, Bugianesi E, Maechesini G, Manzini P, Vanni E, Fargion S. Iron depletion by phebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study. Am J Gastroenterol. 2007;102:1251-8.
66. Vassalle C, Masini S, Bianchi F, Zucchelli GC. Evidence for association between hepatitis C seropositivity and coronary artery disease. Heart. 2004;90:565-6.
67. Warran JH, Martin BC, Krolewski AS, Soeldner JS, Kann CR. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med. 1990;113:909-15.
68. Xu AM, Wang Y, Kershaw H, Xu LY, Lam KSL, Cooper GJS. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest. 2003;112:91-100.
69. Yadav D, Hertan HI, Schweitzer P, Norkus EP, Pitchumoni CS. Serum and liver micronutrient antioxidants and serum oxidative stress in patients with chronic hepatitis C. Am J Gastroenterol. 2002;97:2634-9.
70. Yano M, Hayashi H, Wakusawa S, Sanae F, Takikawa T, Shiono Y, Arao M, Ukai K, Ito H, Watanabe K, Yoshioka K. Long term effects of phlebotomy on biochemical and histological parameters of chronic hepatitis. Am J Gastroenterol. 2002;97:133-7.
71. Yonossi ZM, McCullough AJ, Ong JP, Barnes DS, Post A, TAvill A, Bringman D, Martin LM, Assman J, Gramlich T, Mullen KD, O'Shea R, Carey W, Fergunson R. Obesity and non-alcoholic fatty liver disease in chronic heatitis C. J Clin Gastroenterol. 2004,38:705-9.
72. Zecchin HG, Carvalheira JBC, Saad MJA. Bases moleculares da resistência à insulina. In Godoy-Matos AF, editor. Síndrome Metabólica. São Paulo: Atheneu; 2005.p.19-46.